46 Biggest Movers From Yesterday
Gainers
Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Avadel Shares Fall As FDA Pushes Approval For Its Narcolepsy Treatment Candidate
The FDA has notified Avadel Pharmaceuticals plc (NASDAQ:AVDL) that the review of its marketing application for FT218 is still ongoing, and…
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine candidate VLA2001.
Avadel Pharmaceuticals Announces Ongoing FDA Review Of NDA For FT218 For Patients With Narcolepsy
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October.
The Daily Biotech Pulse: Moderna’s Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.